Novartis forecasts 5% sales growth through 2031 as it raises peak sales estimates
Posted on November 21, 2026
Novartis expects net sales to grow at a constant-currency compound annual rate of 5% between 2026 and 2031, supported by its existing medicines and a pipeline of more than 30 potentially high-value assets.
The company also expects its core operating income margin to return to above 40% by 2029.
Novartis outlined the updated outlook at its Meet Novartis Management event in London, extending its mid-term guidance through 2031.
The company raised peak-sales expectations for three of its major marketed medicines.
Peak sales guidance for multiple sclerosis treatment Kesimpta increased from $6 billion to $8 billion.
The forecast for chronic myeloid leukaemia treatment Scemblix increased from $4 billion to $5 billion, while the estimate for cholesterol-lowering therapy Leqvio was raised from $4 billion to $5 billion.
The revisions follow a recent increase in peak-sales expectations for Rhapsido, or remibrutinib, to $8 billion across chronic spontaneous urticaria, chronic inducible urticaria and relapsing multiple sclerosis.
Novartis said Rhapsido could also generate additional multi-billion-dollar sales across other indications.
The company now identifies nine marketed medicines or franchises with estimated peak-sales potential of between $3 billion and $10 billion.
These include Kisqali, Rhapsido, Cosentyx, Kesimpta, Pluvicto, Scemblix, Leqvio, the Zolgensma franchise and Fabhalta.
Novartis is also relying on its development pipeline to sustain growth beyond the current portfolio.
The company expects more than 35 potentially submission-enabling clinical readouts through 2031.
Its pipeline includes more than 30 assets that Novartis considers potentially high value across cardiovascular, renal and metabolic diseases, immunology, neuroscience and oncology.
More than 20 of these programmes are in registration, Phase III or Phase II development, while more than 10 are in or approaching Phase I.
Ten late-stage programmes have been assigned multi-billion-dollar peak-sales expectations.
Highlighted cardiovascular, renal and metabolic candidates include abelacimab, a Factor XI/XIa inhibitor being developed for stroke prevention in atrial fibrillation, and QCZ484, an siRNA therapy designed for twice-yearly administration in hypertension.
Novartis also highlighted farabursen, a first-in-class miR-17 inhibitor being developed for autosomal dominant polycystic kidney disease.
In immunology, the company is advancing GHZ339, a potential IL-13 and IL-18 bispecific treatment for atopic dermatitis.
Other programmes include Rhapsido in food allergy, ianalumab in systemic lupus erythematosus and the IL-15 inhibitor GIA632 in vitiligo and lichen planus.
Neuroscience programmes highlighted by Novartis include del-brax for facioscapulohumeral muscular dystrophy, del-zota for Duchenne muscular dystrophy amenable to exon 44 skipping and votoplam for Huntington’s disease.
The company’s oncology pipeline includes pelabresib in myelofibrosis and the radioligand therapy candidate 225Ac-PSMA-617 in prostate cancer.
Novartis also highlighted its broader breast cancer pipeline, which includes CDK inhibitors, a pan-mutant PI3Kα inhibitor, radioligand therapies and antibody-drug conjugates.
Chief Executive Vas Narasimhan said the company expects its existing portfolio and upcoming launches to support growth through what Novartis describes as the largest loss-of-exclusivity period in its history.
He added that progress across the company’s Phase I, II and III pipeline supports its expectation of sustained mid-single-digit sales growth over the longer term.
Related Topics and Keywords
Biopharma, Biotechnology, cardiovascular, clinical pipeline, Cosentyx, drug pipeline, Fabhalta, financial outlook, Immunology, Kesimpta, Kisqali, Leqvio, neuroscience, Novartis, Oncology, peak sales, pharma news, pharmaceutical sales, Phase II, phase III, pluvicto, radioligand therapy, remibrutinib, Rhapsido, sales guidance, Scemblix, siRNA, Zolgensma
Subscribe to our FREE newsletter and WEBINAR UPDATES
We will not sell or give your information to a third party. See our Privacy Policy















